Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.
Identifieur interne : 000809 ( PubMed/Corpus ); précédent : 000808; suivant : 000810Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.
Auteurs : Lynda Peterson ; Kathleen P. Ismond ; Elisha Chapman ; Patrick FloodSource :
- Journal of immunology research [ 2314-7156 ] ; 2014.
English descriptors
- KwdEn :
- Adrenergic beta-2 Receptor Agonists (pharmacology), Adrenergic beta-2 Receptor Agonists (therapeutic use), Animals, Humans, Immune System (drug effects), Immune System (metabolism), Neuroprotective Agents (pharmacology), Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (immunology), Parkinson Disease (metabolism), Receptors, Adrenergic, beta-2 (metabolism), Signal Transduction (drug effects).
- MESH :
- chemical , metabolism : Receptors, Adrenergic, beta-2.
- chemical , pharmacology : Adrenergic beta-2 Receptor Agonists, Neuroprotective Agents.
- chemical , therapeutic use : Adrenergic beta-2 Receptor Agonists, Neuroprotective Agents.
- drug effects : Immune System, Signal Transduction.
- drug therapy : Parkinson Disease.
- immunology : Parkinson Disease.
- metabolism : Immune System, Parkinson Disease.
- Animals, Humans.
Abstract
The β2-adrenergic receptor (β2AR) is a seven-transmembrane (7TM) G-protein coupled receptor that is expressed on cells of the pulmonary, cardiac, skeletal muscle, and immune systems. Previous work has shown that stimulation of this receptor on immune cells has profound effects on the regulatory activity of both adaptive and innate immune cells. This review examines the functional dichotomy associated with stimulation of β2AR and microglial cells. As well, recent studies targeting these receptors with long-acting agonists are considered with respect to their therapeutic potential in management of Parkinsonμs disease.
DOI: 10.1155/2014/103780
PubMed: 24741572
Links to Exploration step
pubmed:24741572Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.</title><author><name sortKey="Peterson, Lynda" sort="Peterson, Lynda" uniqKey="Peterson L" first="Lynda" last="Peterson">Lynda Peterson</name><affiliation><nlm:affiliation>Theralogics, Inc., 1829 E. Franklin Street, Chapel Hill, NC 27514-5861, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ismond, Kathleen P" sort="Ismond, Kathleen P" uniqKey="Ismond K" first="Kathleen P" last="Ismond">Kathleen P. Ismond</name><affiliation><nlm:affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3.</nlm:affiliation></affiliation></author><author><name sortKey="Chapman, Elisha" sort="Chapman, Elisha" uniqKey="Chapman E" first="Elisha" last="Chapman">Elisha Chapman</name><affiliation><nlm:affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3.</nlm:affiliation></affiliation></author><author><name sortKey="Flood, Patrick" sort="Flood, Patrick" uniqKey="Flood P" first="Patrick" last="Flood">Patrick Flood</name><affiliation><nlm:affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3 ; North Carolina Oral Health Institute, School of Dentistry, The University of North Carolina at Chapel Hill, Manning Dr. & Columbia Street, Campus Box 7450, Chapel Hill, NC 27599-7450, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24741572</idno><idno type="pmid">24741572</idno><idno type="doi">10.1155/2014/103780</idno><idno type="wicri:Area/PubMed/Corpus">000809</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000809</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.</title><author><name sortKey="Peterson, Lynda" sort="Peterson, Lynda" uniqKey="Peterson L" first="Lynda" last="Peterson">Lynda Peterson</name><affiliation><nlm:affiliation>Theralogics, Inc., 1829 E. Franklin Street, Chapel Hill, NC 27514-5861, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ismond, Kathleen P" sort="Ismond, Kathleen P" uniqKey="Ismond K" first="Kathleen P" last="Ismond">Kathleen P. Ismond</name><affiliation><nlm:affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3.</nlm:affiliation></affiliation></author><author><name sortKey="Chapman, Elisha" sort="Chapman, Elisha" uniqKey="Chapman E" first="Elisha" last="Chapman">Elisha Chapman</name><affiliation><nlm:affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3.</nlm:affiliation></affiliation></author><author><name sortKey="Flood, Patrick" sort="Flood, Patrick" uniqKey="Flood P" first="Patrick" last="Flood">Patrick Flood</name><affiliation><nlm:affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3 ; North Carolina Oral Health Institute, School of Dentistry, The University of North Carolina at Chapel Hill, Manning Dr. & Columbia Street, Campus Box 7450, Chapel Hill, NC 27599-7450, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of immunology research</title><idno type="eISSN">2314-7156</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic beta-2 Receptor Agonists (pharmacology)</term><term>Adrenergic beta-2 Receptor Agonists (therapeutic use)</term><term>Animals</term><term>Humans</term><term>Immune System (drug effects)</term><term>Immune System (metabolism)</term><term>Neuroprotective Agents (pharmacology)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (immunology)</term><term>Parkinson Disease (metabolism)</term><term>Receptors, Adrenergic, beta-2 (metabolism)</term><term>Signal Transduction (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Adrenergic, beta-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adrenergic beta-2 Receptor Agonists</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic beta-2 Receptor Agonists</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Immune System</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Immune System</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The β2-adrenergic receptor (β2AR) is a seven-transmembrane (7TM) G-protein coupled receptor that is expressed on cells of the pulmonary, cardiac, skeletal muscle, and immune systems. Previous work has shown that stimulation of this receptor on immune cells has profound effects on the regulatory activity of both adaptive and innate immune cells. This review examines the functional dichotomy associated with stimulation of β2AR and microglial cells. As well, recent studies targeting these receptors with long-acting agonists are considered with respect to their therapeutic potential in management of Parkinsonμs disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24741572</PMID><DateCreated><Year>2014</Year><Month>04</Month><Day>17</Day></DateCreated><DateCompleted><Year>2015</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2014</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.</ArticleTitle><Pagination><MedlinePgn>103780</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/103780</ELocationID><Abstract><AbstractText>The β2-adrenergic receptor (β2AR) is a seven-transmembrane (7TM) G-protein coupled receptor that is expressed on cells of the pulmonary, cardiac, skeletal muscle, and immune systems. Previous work has shown that stimulation of this receptor on immune cells has profound effects on the regulatory activity of both adaptive and innate immune cells. This review examines the functional dichotomy associated with stimulation of β2AR and microglial cells. As well, recent studies targeting these receptors with long-acting agonists are considered with respect to their therapeutic potential in management of Parkinsonμs disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Lynda</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6186-6460</Identifier><AffiliationInfo><Affiliation>Theralogics, Inc., 1829 E. Franklin Street, Chapel Hill, NC 27514-5861, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismond</LastName><ForeName>Kathleen P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Elisha</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4385-5768</Identifier><AffiliationInfo><Affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flood</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Dentistry, University of Alberta, 7020 Katz Group Centre, Edmonton, AB, Canada T6G 2R3 ; North Carolina Oral Health Institute, School of Dentistry, The University of North Carolina at Chapel Hill, Manning Dr. & Columbia Street, Campus Box 7450, Chapel Hill, NC 27599-7450, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058666">Adrenergic beta-2 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018343">Receptors, Adrenergic, beta-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Glia. 1996 May;17(1):52-62</RefSource><PMID Version="1">8723842</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 1996;14:649-83</RefSource><PMID Version="1">8717528</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1998 Feb 6;242(1):37-40</RefSource><PMID Version="1">9509999</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S146-53</RefSource><PMID Version="1">9817738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurochem Int. 1999 Jul;35(1):47-57</RefSource><PMID Version="1">10403429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 1999 Aug 20;379(1):33-45</RefSource><PMID Version="1">10499369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2005 May 27;308(5726):1314-8</RefSource><PMID Version="1">15831717</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res Brain Res Rev. 1999 Aug;30(2):176-88</RefSource><PMID Version="1">10525174</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1999 Oct;46(4):598-605</RefSource><PMID Version="1">10514096</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci Res. 2005 Aug 1;81(3):390-6</RefSource><PMID Version="1">15948176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Neurobiol. 2005 Jun;76(2):77-98</RefSource><PMID Version="1">16081203</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Paediatr Respir Rev. 2001 Mar;2(1):57-62</RefSource><PMID Version="1">16263481</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2006 Jan 13;281(2):1261-73</RefSource><PMID Version="1">16280323</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurotrauma. 2006 Feb;23(2):170-80</RefSource><PMID Version="1">16503801</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Signal. 2007 Feb;19(2):251-60</RefSource><PMID Version="1">16996249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2007 Jul 15;179(2):1198-209</RefSource><PMID Version="1">17617613</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 2007 Dec 1;575(1-3):57-65</RefSource><PMID Version="1">17869242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Oct 15;22(13):1852-6</RefSource><PMID Version="1">17592621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2008 Feb 29;283(9):5669-76</RefSource><PMID Version="1">18086673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Respir J. 2008 Jun;31(6):1313-21</RefSource><PMID Version="1">18256057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Immunol. 2008 Aug;29(8):357-65</RefSource><PMID Version="1">18599350</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Res. 2008;41(3):155-64</RefSource><PMID Version="1">18512160</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroinflammation. 2008;5:45</RefSource><PMID Version="1">18925972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anesth Analg. 2009 Jan;108(1):3-5</RefSource><PMID Version="1">19095822</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anesth Analg. 2009 Jan;108(1):288-95</RefSource><PMID Version="1">19095864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Glia. 2009 Nov 15;57(15):1600-9</RefSource><PMID Version="1">19330844</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO J. 2010 Oct 6;29(19):3222-35</RefSource><PMID Version="1">20802461</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2011 Apr 1;186(7):4443-54</RefSource><PMID Version="1">21335487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 May;26(6):1072-82</RefSource><PMID Version="1">21626552</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):44-51</RefSource><PMID Version="1">21914456</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosurg Anesthesiol. 2012 Jan;24(1):30-8</RefSource><PMID Version="1">21979171</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Pharmacol Sci. 2012 Oct;33(10):522-30</RefSource><PMID Version="1">22795313</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1258-64</RefSource><PMID Version="1">23781007</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 2006 Apr 10-17;397(1-2):155-8</RefSource><PMID Version="1">16388902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):184-9</RefSource><PMID Version="1">10961382</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cell Sci. 2002 Feb 1;115(Pt 3):455-65</RefSource><PMID Version="1">11861753</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2002 Apr 1;22(7):2434-42</RefSource><PMID Version="1">11923407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2002 May 1;22(9):3673-82</RefSource><PMID Version="1">11978843</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2002 Jun;81(6):1285-97</RefSource><PMID Version="1">12068076</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 2002 Jun 20;446(1-3):25-36</RefSource><PMID Version="1">12098582</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci Res. 2002 Oct 15;70(2):232-7</RefSource><PMID Version="1">12271472</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2003 Sep 11;39(6):889-909</RefSource><PMID Version="1">12971891</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2003 Nov;54(5):599-604</RefSource><PMID Version="1">14595649</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stroke. 2004 May;35(5):1197-202</RefSource><PMID Version="1">15060319</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8603-7</RefSource><PMID Version="1">15173580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1984 Jul 13;48(1):87-92</RefSource><PMID Version="1">6332288</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1987 Jan;84(1):46-50</RefSource><PMID Version="1">3025863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1988 Aug;38(8):1285-91</RefSource><PMID Version="1">3399080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1988 Oct 28;242(4878):540-6</RefSource><PMID Version="1">3140380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1988 Oct;24(4):574-6</RefSource><PMID Version="1">3239957</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1992 Jun 1;148(11):3441-5</RefSource><PMID Version="1">1350291</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharmacol. 1993 Feb;43(2):132-8</RefSource><PMID Version="1">8381505</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 1994 May;62(5):2046-50</RefSource><PMID Version="1">8168970</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1995 Jan;15(1 Pt 1):152-64</RefSource><PMID Version="1">7823126</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1996 Apr 22;717(1-2):44-54</RefSource><PMID Version="1">8738252</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D058666" MajorTopicYN="N">Adrenergic beta-2 Receptor Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018343" MajorTopicYN="N">Receptors, Adrenergic, beta-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3987873</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24741572</ArticleId><ArticleId IdType="doi">10.1155/2014/103780</ArticleId><ArticleId IdType="pmc">PMC3987873</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000809 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000809 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24741572
|texte= Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24741572" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |